A Phase 3, Bridging, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (With or Without Decreased Arousal)

PHASE3CompletedINTERVENTIONAL

Enrollment

193

Participants

Timeline

Start Date

May 10, 2021

Primary Completion Date

May 16, 2023

Study Completion Date

May 16, 2023

Conditions

Hypoactive Sexual Desire Disorder

Interventions

DRUG

Bremelanotide

Subjects will self-administer a fixed dose (1.75 mg) of bremelanotide (BMT) subcutaneously (SC) via auto-injector.

DRUG

Placebo

Subjects will self-administer a Placebo subcutaneously (SC) via auto-injector.

Trial Locations (1)

Seoul National University Hospital, Seoul

All Listed Sponsors

lead

Kwang Dong Pharmaceutical co., ltd.

INDUSTRY